JP Morgan Maintains Neutral on HCA Healthcare, Raises Price Target to $332
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Lisa Gill maintains a Neutral rating on HCA Healthcare (NYSE:HCA) and raises the price target from $327 to $332.
May 30, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Lisa Gill maintains a Neutral rating on HCA Healthcare and raises the price target from $327 to $332.
The Neutral rating suggests that JP Morgan does not expect significant short-term movement in HCA's stock price. However, the slight increase in the price target indicates a modestly positive outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100